-
1
-
-
18844453135
-
Surgery for pancreatic cancer: Recent controversies and current practice
-
Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128: 1626-1641.
-
(2005)
Gastroenterology
, vol.128
, pp. 1626-1641
-
-
Wray, C.J.1
Ahmad, S.A.2
Matthews, J.B.3
-
2
-
-
0032760453
-
AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma
-
American Gastroenterological Association
-
DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999;117:1464-1484.
-
(1999)
Gastroenterology
, vol.117
, pp. 1464-1484
-
-
DiMagno, E.P.1
Reber, H.A.2
Tempero, M.A.3
-
3
-
-
0028799366
-
The National Cancer Data Base report on pancreatic cancer
-
Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671-1677.
-
(1995)
Cancer
, vol.76
, pp. 1671-1677
-
-
Niederhuber, J.E.1
Brennan, M.F.2
Menck, H.R.3
-
4
-
-
0032985541
-
Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database
-
Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
-
(1999)
J Am Coll Surg
, vol.189
, pp. 1-7
-
-
Sener, S.F.1
Fremgen, A.2
Menck, H.R.3
-
5
-
-
0028888708
-
Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?
-
Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221:59-66.
-
(1995)
Ann Surg
, vol.221
, pp. 59-66
-
-
Nitecki, S.S.1
Sarr, M.G.2
Colby, T.V.3
-
6
-
-
0029956221
-
Survival after resection for ductal adenocarcinoma of the pancreas
-
DOI 10.1002/bjs.1800830512
-
Sperti C, Pasquali C, Piccoli A, et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996;83:625-631. (Pubitemid 26163547)
-
(1996)
British Journal of Surgery
, vol.83
, Issue.5
, pp. 625-631
-
-
Sperti, C.1
Pasquali, C.2
Piccoli, A.3
Pedrazzoli, S.4
-
7
-
-
49049101358
-
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
-
Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26: 3496-3502.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3496-3502
-
-
Evans, D.B.1
Varadhachary, G.R.2
Crane, C.H.3
-
8
-
-
38149108387
-
Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer
-
Takai S, Satoi S, Yanagimoto H, et al. Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas. 2008; 36:e26-32.
-
(2008)
Pancreas
, vol.36
-
-
Takai, S.1
Satoi, S.2
Yanagimoto, H.3
-
9
-
-
39749174027
-
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial
-
Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008;26:942-947.
-
(2008)
J Clin Oncol
, vol.26
, pp. 942-947
-
-
Small Jr., W.1
Berlin, J.2
Freedman, G.M.3
-
10
-
-
31544438080
-
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma
-
DOI 10.1245/ASO.2006.03.039
-
Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-158. (Pubitemid 43157408)
-
(2006)
Annals of Surgical Oncology
, vol.13
, Issue.2
, pp. 150-158
-
-
Talamonti, M.S.1
Small Jr., W.2
Mulcahy, M.F.3
Wayne, J.D.4
Attaluri, V.5
Colletti, L.M.6
Zalupski, M.M.7
Hoffman, J.P.8
Freedman, G.M.9
Kinsella, T.J.10
Philip, P.A.11
McGinn, C.J.12
-
11
-
-
34447121503
-
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer
-
Vento P, Mustonen H, Joensuu T, et al. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol. 2007;13:2945-2951. (Pubitemid 47033753)
-
(2007)
World Journal of Gastroenterology
, vol.13
, Issue.21
, pp. 2945-2951
-
-
Vento, P.1
Mustonen, H.2
Joensuu, T.3
Karkkainen, P.4
Kivilaakso, E.5
Kiviluoto, T.6
-
12
-
-
0034880820
-
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma
-
Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001;7:2246-2253. (Pubitemid 32751621)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.8
, pp. 2246-2253
-
-
Wolff, R.A.1
Evans, D.B.2
Gravel, D.M.3
Lenzi, R.4
Pisters, P.W.T.5
Lee, J.E.6
Janjan, N.A.7
Charnsangavej, C.8
Abbruzzese, J.L.9
-
13
-
-
23744508312
-
Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head
-
DOI 10.1245/ASO.2005.05.028
-
Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. Ann Surg Oncol. 2005;12:629-636. (Pubitemid 41126092)
-
(2005)
Annals of Surgical Oncology
, vol.12
, Issue.8
, pp. 629-636
-
-
Ohigashi, H.1
Ishikawa, O.2
Eguchi, H.3
Sasaki, Y.4
Yamada, T.5
Noura, S.6
Murata, K.7
Takachi, K.8
Miyashiro, I.9
Doki, Y.10
Imaoka, S.11
Kasugai, T.12
Nishiyama, K.13
-
14
-
-
20244385572
-
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer
-
DOI 10.1245/ASO.2005.03.105
-
White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214-221. (Pubitemid 40568908)
-
(2005)
Annals of Surgical Oncology
, vol.12
, Issue.3
, pp. 214-221
-
-
White, R.R.1
Xie, H.B.2
Gottfried, M.R.3
Czito, B.G.4
Hurwitz, H.I.5
Morse, M.A.6
Blobe, G.C.7
Paulson, E.K.8
Baillie, J.9
Branch, M.S.10
Jowell, P.S.11
Clary, B.M.12
Pappas, T.N.13
Tyler, D.S.14
-
15
-
-
0037317521
-
The role of p53 in determining sensitivity to radiotherapy
-
Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117-129.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 117-129
-
-
Gudkov, A.V.1
Komarova, E.A.2
-
16
-
-
0345256634
-
The role of p53 in chemosensitivity and radiosensitivity
-
El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22:7486-7495.
-
(2003)
Oncogene
, vol.22
, pp. 7486-7495
-
-
El-Deiry, W.S.1
-
17
-
-
40749094856
-
Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer
-
DOI 10.1016/S1470-2045(08)70073-1, PII S1470204508700731
-
Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008;9:288-296. (Pubitemid 351722948)
-
(2008)
The Lancet Oncology
, vol.9
, Issue.3
, pp. 288-296
-
-
Bussink, J.1
Van Der Kogel, A.J.2
Kaanders, J.H.3
-
18
-
-
34948822244
-
Molecular imaging of Akt kinase activity
-
DOI 10.1038/nm1608, PII NM1608
-
Zhang L, Lee KC, Bhojani MS, et al. Molecular imaging of Akt kinase activity. Nat Med. 2007;13:1114-1119. (Pubitemid 47517501)
-
(2007)
Nature Medicine
, vol.13
, Issue.9
, pp. 1114-1119
-
-
Zhang, L.1
Lee, K.C.2
Bhojani, M.S.3
Khan, A.P.4
Shilman, A.5
Holland, E.C.6
Ross, B.D.7
Rehemtulla, A.8
-
19
-
-
1842484829
-
Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection
-
DOI 10.1038/sj.onc.1207392
-
Nakamura T, Furukawa Y, Nakagawa H, et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004;23: 2385-2400. (Pubitemid 38496794)
-
(2004)
Oncogene
, vol.23
, Issue.13
, pp. 2385-2400
-
-
Nakamura, T.1
Furukawa, Y.2
Nakagawa, H.3
Tsunoda, T.4
Ohigashi, H.5
Murata, K.6
Ishikawa, O.7
Ohgaki, K.8
Kashimura, N.9
Miyamoto, M.10
Hirano, S.11
Kondo, S.12
Katoh, H.13
Nakamura, Y.14
Katagiri, T.15
-
20
-
-
0037427784
-
Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas
-
DOI 10.1002/ijc.10788
-
Violette S, Festor E, Pandrea-Vasile I, et al. Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer. 2003;103:185-193. (Pubitemid 35461510)
-
(2003)
International Journal of Cancer
, vol.103
, Issue.2
, pp. 185-193
-
-
Violette, S.1
Festor, E.2
Pandrea-Vasile, I.3
Mitchell, V.4
Adida, C.5
Dussaulx, E.6
Lacorte, J.-M.7
Chambaz, J.8
Lacasa, M.9
Lesuffleur, T.10
-
21
-
-
18644386654
-
Reg protein is overexpressed in gastric cancer cells, where it activates a signal transduction pathway that converges on ERK1/2 to stimulate growth
-
DOI 10.1016/S0014-5793(02)03398-7, PII S0014579302033987
-
Kadowaki Y, Ishihara S, Miyaoka Y, et al. Reg protein is overexpressed in gastric cancer cells, where it activates a signal transduction pathway that converges on ERK1/2 to stimulate growth. FEBS Lett. 2002;530:59-64. (Pubitemid 35248186)
-
(2002)
FEBS Letters
, vol.530
, Issue.1-3
, pp. 59-64
-
-
Kadowaki, Y.1
Ishihara, S.2
Miyaoka, Y.3
Rumi, M.A.K.4
Sato, H.5
Kazumori, H.6
Adachi, K.7
Takasawa, S.8
Okamoto, H.9
Chiba, T.10
Kinoshita, Y.11
-
22
-
-
16844362558
-
Reg IV: A promising marker of hormone refractory metastatic prostate cancer
-
DOI 10.1158/1078-0432.CCR-04-0356
-
Gu Z, Rubin MA, Yang Y, et al. Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005;11: 2237-2243. (Pubitemid 40490182)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.6
, pp. 2237-2243
-
-
Gu, Z.1
Rubin, M.A.2
Yang, Y.3
Deprimo, S.E.4
Zhao, H.5
Horvath, S.6
Brooks, J.D.7
Loda, M.8
Reiter, R.E.9
-
23
-
-
26044463766
-
Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma
-
DOI 10.1002/path.1827
-
Oue N, Mitani Y, Aung PP, et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol. 2005;207:185-198. (Pubitemid 41404149)
-
(2005)
Journal of Pathology
, vol.207
, Issue.2
, pp. 185-198
-
-
Que, N.1
Mitani, Y.2
Aung, P.P.3
Sakakura, C.4
Takeshima, Y.5
Kaneko, M.6
Noguchi, T.7
Nakayama, H.8
Yasui, W.9
-
24
-
-
33748932541
-
Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4
-
DOI 10.1111/j.1349-7006.2006.00297.x
-
Takehara A, Eguchi H, Ohigashi H, et al. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006;97: 1191-1197. (Pubitemid 44430644)
-
(2006)
Cancer Science
, vol.97
, Issue.11
, pp. 1191-1197
-
-
Takehara, A.1
Eguchi, H.2
Ohigashi, H.3
Ishikawa, O.4
Kasugai, T.5
Hosokawa, M.6
Katagiri, T.7
Nakamura, Y.8
Nakagawa, H.9
-
25
-
-
30044442435
-
Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas
-
DOI 10.1053/j.gastro.2005.10.001, PII S001650850502010X
-
Bishnupuri KS, Luo Q, Murmu N, et al. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology. 2006;130:137-149. (Pubitemid 43049844)
-
(2006)
Gastroenterology
, vol.130
, Issue.1
, pp. 137-149
-
-
Bishnupuri, K.S.1
Luo, Q.2
Murmu, N.3
Houchen, C.W.4
Anant, S.5
Dieckgraefe, B.K.6
-
26
-
-
34347348170
-
Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy
-
DOI 10.1038/sj.onc.1210215, PII 1210215
-
Mitani Y, Oue N, Matsumura S, et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007;26:4383-4393. (Pubitemid 47014457)
-
(2007)
Oncogene
, vol.26
, Issue.30
, pp. 4383-4393
-
-
Mitani, Y.1
Oue, N.2
Matsumura, S.3
Yoshida, K.4
Noguchi, T.5
Ito, M.6
Tanaka, S.7
Kuniyasu, H.8
Kamata, N.9
Yasui, W.10
-
27
-
-
0026454511
-
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas
-
Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
-
(1992)
Arch Surg
, vol.127
, pp. 1335-1339
-
-
Evans, D.B.1
Rich, T.A.2
Byrd, D.R.3
-
28
-
-
33846405332
-
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial
-
DOI 10.1001/jama.297.3.267
-
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277. (Pubitemid 46143304)
-
(2007)
Journal of the American Medical Association
, vol.297
, Issue.3
, pp. 267-277
-
-
Oettle, H.1
Post, S.2
Neuhaus, P.3
Gellert, K.4
Langrehr, J.5
Ridwelski, K.6
Schramm, H.7
Fahlke, J.8
Zuelke, C.9
Burkart, C.10
Gutberlet, K.11
Kettner, E.12
Schmalenberg, H.13
Weigang-Koehler, K.14
Bechstein, W.-O.15
Niedergethmann, M.16
Schmidt-Wolf, I.17
Roll, L.18
Doerken, B.19
Riess, H.20
more..
-
29
-
-
0041564101
-
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy
-
DOI 10.1016/S0360-3016(03)00524-8
-
Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:90-97. (Pubitemid 36959743)
-
(2003)
International Journal of Radiation Oncology Biology Physics
, vol.57
, Issue.1
, pp. 90-97
-
-
Micke, O.1
Bruns, F.2
Kurowski, R.3
Horst, E.4
Devries, A.F.5
Hausler, J.W.6
Willich, N.7
Schafer, U.8
-
30
-
-
0034009704
-
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
-
Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-1016. (Pubitemid 30128852)
-
(2000)
British Journal of Cancer
, vol.82
, Issue.5
, pp. 1013-1016
-
-
Halm, U.1
Schumann, T.2
Schiefke, I.3
Witzigmann, H.4
Mossner, J.5
Keim, V.6
-
31
-
-
0030273040
-
CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer
-
Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg. 1996;172:350-352.
-
(1996)
Am J Surg
, vol.172
, pp. 350-352
-
-
Willett, C.G.1
Daly, W.J.2
Warshaw, A.L.3
-
32
-
-
0031874821
-
Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer
-
Okusaka T, Okada S, Sato T, et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology. 1998;45:867-872. (Pubitemid 28321071)
-
(1998)
Hepato-Gastroenterology
, vol.45
, Issue.21
, pp. 867-872
-
-
Okusaka, T.1
Okada, S.2
Sato, T.3
Wakasugi, H.4
Saisho, H.5
Furuse, J.6
Ishikawa, O.7
Matsuno, S.8
Yokoyama, S.9
-
33
-
-
0034937881
-
Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer
-
Ohara K, Tatsuzaki H, Molotkova NG, et al. Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology. 2001;48:859-863. (Pubitemid 32619699)
-
(2001)
Hepato-Gastroenterology
, vol.48
, Issue.39
, pp. 859-863
-
-
Ohara, K.1
Tatsuzaki, H.2
Molotkova, N.G.3
Oda, T.4
Yuzawa, K.5
Saida, Y.6
Matsuzaki, Y.7
Shimizu, W.8
Todoroki, T.9
Fukao, K.10
Tanaka, N.11
Itai, Y.12
-
34
-
-
0038199686
-
CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy
-
Micke O, Bruns F, Schafer U, et al. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003;23:835-840. (Pubitemid 36750881)
-
(2003)
Anticancer Research
, vol.23
, Issue.2 A
, pp. 835-840
-
-
Micke, O.1
Bruns, F.2
Schafer, U.3
Kurowski, R.4
Horst, E.5
Willich, N.6
|